Infertility Drugs Market Synopsis:
Infertility Drugs Market Size Was Valued at USD 3.66 Billion in 2023, and is Projected to Reach USD 6.51 Billion by 2032, Growing at a CAGR of 6.6% From 2024-2032.
The market of infertility drugs consists of a number of medicines that are used to solve different types of infertility both in men and women. The management of ovulation, improvement of fertility, and promotion of assisted reproductive technologies including IVF are goals of these drugs. These include demographic characteristics for this market that are; rising incidences of infertility, modern developments in reproductive science, and fertility solutions acceptance.
The market for infertility drugs has recorded considerable growth in recent years due to increased cases of infertility throughout the world. This can be attributed to late pregnancies as a result of change of lifestyle, macode-PCOS among women and increased publicity among the population on matters concerning fertility. Specific range of products is present at the market including hormonal therapies, ovulation stimulants, assisted reproductive technology and many others. Also, the enhance utilization of in vitro fertilization, intrauterine insemination procedures have positively impacted the market for fertility drugs.
Concerning the market dynamics, the companies are focused on the research & development of new drugs and therapies. The trend towards individualized approach to fertility treatments also influences the market of infertility drugs. In addition, there is increasing propensity of joint ventures between manufacturers of drugs and infertility clinics to improve the distribution of infertility treatments and increase their availability to patients. The technology that enables the use of the digital health platforms and telemedicine in the management of fertility treatment is also growing as a trend that enhance patient care.
Infertility Drugs Market Trend Analysis:
Rise of Personalized Medicine in Infertility Treatments
- Some of the trends of goal front in infertility drugs market are: • One of them is that the market is moving in the direction of more targeted treatment or as it called the pharmacogenomics. New technologies in genomic science and reproductive biology are providing a foundation to backtrack the specific causes for infertility in every couple. This is because a large number of treatment options leads to focused and efficient outcomes that can boost the conception rates while satisfying the needs of the patients. Due to the growing interest of healthcare providers and pharmaceutical companies in genetic tests, genetics, and genetic approaches to treatment, the market for infertility drugs should expect further evolution of existing therapies as products.
Expanding Access to Fertility Treatments
- The rising knowledge and demand for infertility treatments form promising prospects for market development. At the present time, more people and couples are looking to fertility treatment that is why it is necessary to have cheap and available infertility medications. Tele-medicine and new methods of the digital platforms can make fertility treatments closer to patients and become more attainable. In the same way, market growth can further be boosted by necessity – through efforts made by governments and organisations which focus on fertility awareness and education. Players whose strategic objectives involve diversification and the streamlining of logistics can probably gain much from this blossoming market.
Infertility Drugs Market Segment Analysis:
Infertility Drugs Market is Segmented on the basis of Drug, Route of Administration, End User, and Region
By Drug class, Gonadotropins segment is expected to dominate the market during the forecast period
- The market is expected to be led by the Gonadotropins segment during the forecast period as it plays a significant role in the ovarian function, and in improving the fertility and recipients involved in ART. FSH and LH are the hormones which are used in numerous fertility therapies, for example, IVF, IUI, etc. In addition to this, the cases of infertility have been rising globally, and due to the growing use of the newly developed technology in fertility treatments, the drugs are also in high demand. In addition, research and development currently underway focusing on the enhancement of the effectiveness and safety of gonadotropin preparations should provide fillip to the product’s position within the market, making it a favourite amongst practitioners and consumers alike.
By Route of Adminstration, Oral segment expected to held the largest share
- The Oral segment has a higher market share in the global infertility drugs market during the forecast period due to the side-effect free feature associated with the oral medicines segment. Selective estrogenic receptor modulators and aromatase inhibitors are commonly prescribed oral fertility medicines mostly because patients enjoy non-invasive procedures, and doctors can prescribe them for self-administration at home. It is not only a talking point for patient’s compliance, but it can equally eliminate or minimize frequent health check-up that is characteristic of injectable methods of administration. Moreover, the increasing need for over-the-counter fertility products that are easier to use also contributing towards demand of oral medications possibly considered as one of the dominating segments in the market.
Infertility Drugs Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- The overall Infertility drugs market in North America held a 35 % share in 2023, due to new launches and acceptance of multi-infertility medicines. This dominance has been however boosted by research activities currently being conducted in the area of infertility which is expected to open up other opportunities in the region. Increased frequency of menopausal disorders, urinary infections, thyroid ailments and endometrial diseases, and a high prevalence of PCOS affecting more than 5 million women of child bearing age enhances the need for fertility treatments. Furthermore, given increasing work demands, time management problems and elevated stress levels in women, the demand for precise and efficient treatment is expected to grow. According to Statistics Canada, there was a bad year in 2020, whereby the fertility rate reduced, meaning that the demand for fertility products is on the rise as people who are facing challenges in conceiving increase.
Active Key Players in the Infertility Drugs Market:
- AbbVie Inc. (United States)
- Bayer AG (Germany)
- EMD Serono (United States)
- Ferring Pharmaceuticals (Switzerland)
- Genea Limited (Australia)
- Haplogen (United States)
- HCG Clinics (United States)
- Igenomix (Spain)
- Irvine Scientific (United States)
- IVFtech ApS (Denmark)
- Merck & Co., Inc. (United States)
- OvaScience (United States)
- ReproTech, LLC (United States)
- SAGE Therapeutics (United States)
- Thermo Fisher Scientific (United States)
- Other Active Players
Key Industry Developments in the Infertility Drugs Market:
- In May 2024, Turkey asked India for Gonadotropin medications, which are used in obstetrics and gynecologist, because of the high demand for IVF procedures there.
- In February 2024, with approval from the US Food and Drug Administration (FDA), Lupin Limited launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe in the US market. This medicine is intended to treat infertility and is a generic version of Ganirelix Acetate Injection, the reference listed drug (RLD) of Organon USA LLC.
- In February 2023, Russia started producing two more IVF drugs and recombinant follicle-stimulating hormone on its own soil.
|
Infertility Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.66 Billion |
|
Forecast Period 2024-32 CAGR: |
6.6 % |
Market Size in 2032: |
USD 6.51 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route Of Administration |
|
||
|
By End Users |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Infertility Drugs Market by Drug class
4.1 Infertility Drugs Market Snapshot and Growth Engine
4.2 Infertility Drugs Market Overview
4.3 Gonadotropins
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Gonadotropins: Geographic Segmentation Analysis
4.4 Aromatase Inhibitors
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Aromatase Inhibitors: Geographic Segmentation Analysis
4.5 SERMs
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 SERMs: Geographic Segmentation Analysis
4.6 Dopamine Agonists
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Dopamine Agonists: Geographic Segmentation Analysis
Chapter 5: Infertility Drugs Market by Route of Administration
5.1 Infertility Drugs Market Snapshot and Growth Engine
5.2 Infertility Drugs Market Overview
5.3 Oral and Parenteral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral and Parenteral: Geographic Segmentation Analysis
Chapter 6: Infertility Drugs Market by End User
6.1 Infertility Drugs Market Snapshot and Growth Engine
6.2 Infertility Drugs Market Overview
6.3 Men
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Men: Geographic Segmentation Analysis
6.4 Women
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Women: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Infertility Drugs Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 FERRING PHARMACEUTICALS (SWITZERLAND)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 MERCK & CO. INC. (UNITED STATES)
7.4 BAYER AG (GERMANY)
7.5 ABBVIE INC. (UNITED STATES)
7.6 OTHER ACTIVE PLAYERS
Chapter 8: Global Infertility Drugs Market By Region
8.1 Overview
8.2. North America Infertility Drugs Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug class
8.2.4.1 Gonadotropins
8.2.4.2 Aromatase Inhibitors
8.2.4.3 SERMs
8.2.4.4 Dopamine Agonists
8.2.5 Historic and Forecasted Market Size By Route of Administration
8.2.5.1 Oral and Parenteral
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 Men
8.2.6.2 Women
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Infertility Drugs Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug class
8.3.4.1 Gonadotropins
8.3.4.2 Aromatase Inhibitors
8.3.4.3 SERMs
8.3.4.4 Dopamine Agonists
8.3.5 Historic and Forecasted Market Size By Route of Administration
8.3.5.1 Oral and Parenteral
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 Men
8.3.6.2 Women
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Infertility Drugs Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug class
8.4.4.1 Gonadotropins
8.4.4.2 Aromatase Inhibitors
8.4.4.3 SERMs
8.4.4.4 Dopamine Agonists
8.4.5 Historic and Forecasted Market Size By Route of Administration
8.4.5.1 Oral and Parenteral
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 Men
8.4.6.2 Women
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Infertility Drugs Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug class
8.5.4.1 Gonadotropins
8.5.4.2 Aromatase Inhibitors
8.5.4.3 SERMs
8.5.4.4 Dopamine Agonists
8.5.5 Historic and Forecasted Market Size By Route of Administration
8.5.5.1 Oral and Parenteral
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 Men
8.5.6.2 Women
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Infertility Drugs Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug class
8.6.4.1 Gonadotropins
8.6.4.2 Aromatase Inhibitors
8.6.4.3 SERMs
8.6.4.4 Dopamine Agonists
8.6.5 Historic and Forecasted Market Size By Route of Administration
8.6.5.1 Oral and Parenteral
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 Men
8.6.6.2 Women
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Infertility Drugs Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug class
8.7.4.1 Gonadotropins
8.7.4.2 Aromatase Inhibitors
8.7.4.3 SERMs
8.7.4.4 Dopamine Agonists
8.7.5 Historic and Forecasted Market Size By Route of Administration
8.7.5.1 Oral and Parenteral
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 Men
8.7.6.2 Women
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Infertility Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.66 Billion |
|
Forecast Period 2024-32 CAGR: |
6.6 % |
Market Size in 2032: |
USD 6.51 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route Of Administration |
|
||
|
By End Users |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
